Dosing initiated in Ph III balaglitazone trial
Danish biopharmaceutical company Rheoscience AS and Indian drugmaker Dr Reddy's have begun dosing patients in a Phase III trial of the co-developed insulin sensitizer balaglitazone (DRF2593-307).The drug, which is an oral partial peroxisome proliferator-activated receptor gamma agonist, is designed for the treatment of type 2 diabetes.
The current study, which will run for a period of six months, will provide participants with one of two daily doses of balaglitazone (10mg or 20mg), Eli Lilly's comparator product Actos (pioglitazone), or placebo. The program's primary endpoints are defined as the change in A1c levels over time, and non-inferiority to Actos.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze